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A B S T R A C T
It is well-established that immunocompromised people are at increased risk of HPV-related disease compared
with those who are immunocompetent. Prophylactic HPV sub-unit vaccines are safe and immunogenic in
immunocompromised people and it is strongly recommended that vaccination occur according to national
guidelines. When delivered to immunocompromised populations, HPV vaccines should be given as a 3-dose
regimen.
1. Introduction
For the immunocompetent host, there are clear guidelines on the
use of prophylactic human papillomavirus [HPV] vaccines (bivalent
[2vHPV], quadrivalent [4vHPV] and nonavalent [9vHPV]) available
from various international public health authorities, regulatory agen-
cies and societies. These include the World Health Organisation
(WHO) [1,2], European Medicines Agency (EMA) [3,4], as well as
numerous national advisory committees worldwide, such as the Food
and Drug Administration (FDA), US Advisory Committee on
Immunisation Practices (ACIP) [5–10] American Society of Clinical
Oncology [ASCO], Australian Therapeutic Goods Administration
(TGA), Australian Technical Advisory Group on Immunisation [11],
National Advisory Committee on Immunisation (NACI) in Canada
[12], and International Papillomavirus Society (IPVS) [13]. The
currently licensed vaccines are viral-like-particles, which are subunit,
non-replicating, and do not contain any infectious component. There is
good evidence that HPV 16 and 18 contribute globally to 70% of
cervical cancers [14], 78% of HPV related vulvar cancer [15], 65% of
vaginal [16] and 90% of anal cancers in both sexes [17], as well as a
geographically variable proportion of oropharyngeal cancers. Hence,
the expected reduction in disease is substantial for those vaccinated
with the 2vHPV or 4vHPV vaccine when given prior to HPV infection.
Moreover, with the new 9vHPV vaccine, the proportion of the cancer
burden that is potentially preventable in women rises an incremental
amount to approximately 90% [18,19], 92% [15], 86% [16] and 95%
[17], respectively, for cervical, vulvar, vaginal and vulvar cancer. These
guidelines generally focus attention on vaccination of female preado-
lescents (target age is country-specific and dependent upon delivery
strategy) from 9 to 14 years of age and prior to sexual debut, although
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some have included a catch-up period up to 26 years of age. In some
countries, there is a gender-neutral approach including boys. Based on
immunogenicity data, and following endorsement from the WHO in
2014, a two-dose regimen is now recommended in many countries for
immunocompetent individuals aged under 15 years at receipt of the
first vaccine dose, with a dose interval of at least 6 months. Those who
are 15 years or older at first dose, or those who are immunocompro-
mised, require the standard three-dose vaccination schedule [1].
Guidelines for HPV vaccination of the immunocompromised host
are provided in some countries by specialist immunisation advisory
groups or societies [20–24]. In many countries immunisation for these
groups is recommended, regardless of age, but not nationally funded.
In this position statement, we outline the rationale for ensuring that
clinicians, patients and policy makers explicitly consider the potential
role of HPV vaccination in immunocompromised individuals.
2. Immunocompromised hosts
Immunocompromised hosts include those with infections affecting
immune competency such as human immunodeficiency virus (HIV),
and those on immunosuppressive and/or immunomodulatory treat-
ment for autoimmune conditions (e.g. multiple sclerosis, inflammatory
bowel disease, systemic lupus erythematosus (SLE)), or for prevention
of graft rejection among those who are post-transplantation.
It has been well documented that HIV-positive women, have an
overall higher prevalence of HPV DNA two or threefold higher than
HIV negative women [25] (60–70%), have a higher prevalence of high-
risk-HPV DNA (20–35%) [26], types that are known to cause cancer,
more likely to have multiple HPV types present (35–50%) [25], higher
HPV viral loads (45–60%) [25] and persistent HR-HPV infections
(45% vs 15%) [25–29]. Notably a lower CD4 count in female patients is
strongly associated with cervical and anal high grade squamous
intraepithelial lesions (HSIL). There is also a greater risk of vulvar
HSIL [30], a 10-fold greater risk of anal cancer [31] and a three to five
fold higher risk for cervical SIL, with invasive cervical cancer being an
AIDS-defining illness [32–36]. In addition for males and females who
are HIV-positive there is a higher risk of HR-HPV anal infection, anal
HSIL and anal cancer [37,38]. Although this association is presumably
due to impaired ability to clear HPV and increased reactivation of
latent infection [39–45], other mechanisms may be involved that result
in cellular immune dysfunction [46,47].
Those who are immunocompromised for reasons other than HIV
infection are also at increased risk of HPV infection, HSIL and cancer
compared with immunocompetent individuals [25–36,39,40,43,45,
48–54]. For example, prior to prophylactic vaccines being available,
bone marrow transplantation patients had a higher rate of cervical HSIL
than in the age-adjusted general population [48]. Moreover, it was
recognised that allogeneic transplant recipients had a higher rate of
cervical abnormalities than did patients receiving autologous transplants
[48,54]. Higher rates of cervical abnormalities have also been found in
studies of women with SLE, rheumatoid arthritis and inflammatory
bowel disease when on immunosuppressant medications [43,45].
Individuals who are HIV positive remain at risk for acquiring new
HPV infections which likely can be prevented by HPV vaccination. This
includes prevention of HR infections that can progress to HSIL. It is to
be noted that highly active antiretroviral therapy (HAART) has modest
effect or no effect on HPV carriage, clearance or persistence [28],
although recent reports suggest a decline in cervical HSIL [55]. Recent
studies show that management guidelines for women on HAART with
HIV viral suppression, can parallel guidelines for healthy women [56].
Moreover, immunosuppressed patients are also at a higher risk of HSIL
due to low risk HPV types [57–59]. In those who are HIV-positive, as
all immunosuppressed peoples, there is also greater risk of genital
warts being recalcitrant to treatment [30].
2.1. A growing evidence base: HPV vaccine studies in
immunocompromised people
The increased risk of HPV infection and associated diseases in
immunocompromised men and women warrants a strong emphasis on
vaccinating these individuals according to the relevant national guide-
lines. Individuals who meet these guidelines may be vaccinated while
immunocompromised or ideally, prior to the development of immu-
nocompromised status.
The 4vHPV vaccine has been administered to HIV-positive children
7–12 years of age with seroconversion rates greater than 96% [60].
Antibody titres for HPV 6/11/16/18, were 30–50% lower compared
with historical age-matched controls, but higher than natural infections
and in the range where clinical efficacy is seen in adults [60]. Studies in
vertically-acquired HIV-positive adolescents adult men and women
show high rates of seroconversion (95–100%), with no adverse effects
on CD4 or plasma HIV RNA levels [61–68]. We currently await efficacy
data, although 4vHPV vaccine will likely benefit immunocompromised
men and women when vaccinated in the recommended age range,
despite the lower titres seen in this population.
For the 2vHPV vaccine, similar studies in HIV-positive women
demonstrated high seroconversion rates, and sustained positivity for
anti-HPV 16 and 18 over 12 months. Although lower antibody titres
were seen than in HIV-negative controls, the titres remained well above
levels seen following natural infection [69]. As with the 4vHPV vaccine,
the 2vHPV vaccine showed no adverse effect on CD4 count over time,
nor effect on HIV viral load over time: however these studies have been
performed in largely HIV positive subjects enrolled with reasonably
high CD4 counts.
Vaccination in other immunocompromised groups, including pa-
tients with solid organ transplants and autoimmune disorders have
demonstrated lower titres of antibodies in these patients compared
with controls. These included patients with juvenile idiopathic arthritis,
SLE, juvenile dermatomyositis, and kidney and lung transplant [70–
73]. One study noted that titres appeared to differ by type of
immunosuppressive drug treatment, with patients on mycophenolate
producing lower HPV antibody titres than patients on other drugs [73].
Another study indicated that lung transplant patients had much lower
antibodies than other solid organ transplant recipients [70]. However,
these studies all showed that the vaccines were safe and consistently
found that HPV vaccination was not associated with significant adverse
effects and importantly, the clinical course of these diseases were also
not affected [73–75].
Given that the recommendation for two dose schedules of HPV
vaccines is currently based upon bridging data, showing equivalent
immunogenicity in immunocompetent young adolescents as three
doses in older persons in whom efficacy has been assessed, there is
no current evidence to support equivalence in immunocompromised
individuals. Consequently, the recommendations for those who are
immunosuppressed or HIV-positive should be for 3 doses, within the
recommended age guidelines and as early as possible prior to the onset
of immunocompromise. Continued research in this group of vaccine
recipients is necessary.
3. Screening remains important
Currently screening remains a critical component of cervical cancer
prevention for all women, regardless of HPV vaccination status. Because of
their increased risk of cervical HSIL and cervical cancer, risk of disease due
to non-vaccine HPV types and the lack of efficacy studies post-vaccination,
secondary prevention through screening remains critical for immunocom-
promised women, regardless of HPV vaccination status. Most countries
recommend more frequent screening for these women than for the general
population on the basis of their higher risk [76–79]. Studies are in progress
to determine whether screening for, and treatment of, anal HSIL is of value
in preventing anal cancer in at-risk populations [80–82].
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4. Key points
IPVS statement on HPV vaccination and immunocompro-
mised hosts
• Immunocompromised people are at increased risk of HPV-related
disease, compared with immunocompetent people.
HPV vaccination is safe in immunocompromised people (e.g.,
HIV-positive [+] individuals, transplant recipients).
• Current vaccines are simple, non-replicating subunit vaccines and
hence, not infectious.
• Given current knowledge, HPV vaccines will likely benefit
immunocompromised men and women, especially when
vaccinated in the recommended age range.
• It is ideal to vaccinate everyone according to national guidelines,
before people become immunocompromised.
• For those who are immunocompromised at the time of
vaccination, 3 doses are currently recommended.
• Antibody titres in response to vaccination are often lower than
those in immunocompetent people, but the clinical relevance of
this is yet unknown. Efficacy data following vaccination in
immunocompromised people are very limited to date.
• Vaccines that have broad coverage or cross-coverage should be
encouraged for HIV (+) men and women given growing evidence
that the distribution of HPV types in cancers may be broader
than that seen in the immunocompetent population.
• Cervical cancer screening remains an important public health
complement to HPV vaccination for the prevention of cervical
cancer.
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